Neurocrine Biosciences Debt Securities, Available-for-Sale, Unrealized Loss Position increased by 371.5% to $1.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 398.0%, from $317.30M to $1.58B. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates a broader decline in the market value of the debt portfolio relative to its cost basis.
The aggregate fair value of all debt securities classified as available-for-sale that are currently in an unrealized los...
Used to gauge the overall sensitivity of the investment portfolio to market price changes.
other_debt_securities_available_for_sale_unrealized_loss_ab3ae9| Q2 '21 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|
| Value | $245.50M | $458.70M | $317.30M | $401.80M | $349.80M | $335.10M | $1.58B |
| QoQ Change | — | +86.8% | -30.8% | +26.6% | -12.9% | -4.2% | +371.5% |
| YoY Change | — | — | — | — | — | -26.9% | +398.0% |